Beam Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 5, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 5, 2024

BEAM$25.15-6.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’
	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balance at December 31, 2022	71,277,339	$712	$1,792,554	$(2,430)	$(1,057,362)	$733,474
Purchase of common stock under ESPP	65,620	1	1,707	—	—	1,708
Issuance of common stock from At-the-Market offering, net of issuance costs of $0.2 million	2,431,770	24	93,786	—	—	93,810
Vesting of restricted common stock	284,858	3	(3)	—	—	—
Stock-based compensation	—	—	23,917	—	—	23,917
Exercise of common stock options	375,805	4	3,388	—	—	3,392
Other comprehensive income (loss)	—	—	—	1,665	—	1,665
Net loss	—	—	—	—	(96,460)	(96,460)
Balance at March 31, 2023	74,435,392	$744	$1,915,349	$(765)	$(1,153,822)	$761,506
Issuance of common stock from At-the-Market offering, net of issuance costs of $5.1 million	3,387,358	34	107,149	—	—	107,183
Vesting of restricted common stock	63,154	1	(1)	—	—	—
Stock-based compensation	—	—	26,278	—	—	26,278
Exercise of common stock options	67,598	1	701	—	—	702
Other comprehensive income (loss)	—	—	—	(1,250)	—	(1,250)
Net loss	—	—	—	—	(82,776)	(82,776)
Balance at June 30, 2023	77,953,502	$780	$2,049,476	$(2,015)	$(1,236,598)	$811,643
Purchase of common stock under ESPP	64,783	1	1,323	—	—	1,324
Issuance of common stock from At-the-Market offering, net of issuance costs of $0.8 million	1,133,575	10	34,934	—	—	34,944
Vesting of restricted common stock	68,869	1	(1)	—	—	—
Stock-based compensation	—	—	25,835	—	—	25,835
Exercise of common stock options	161,303	2	1,290	—	—	1,292
Other comprehensive income (loss)	—	—	—	(9)	—	(9)
Net loss	—	—	—	—	(96,088)	(96,088)
Balance at September 30, 2023	79,382,032	$794	$2,112,857	$(2,024)	$(1,332,686)	$778,941

Condensed Consolidated Statements of Stockholders’ Equity - Continued

(in thousands, except share amounts)

Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’
	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balance at December 31, 2023	81,632,496	$816	$2,169,798	$604	$(1,189,889)	$981,329
Purchase of common stock under ESPP	76,461	1	1,397	—	—	1,398
Vesting of restricted common stock	420,579	4	(4)	—	—	—
Stock-based compensation	—	—	29,281	—	—	29,281
Exercise of common stock options	151,291	2	1,674	—	—	1,676
Other comprehensive income (loss)	—	—	—	(1,525)	—	(1,525)
Net loss	—	—	—	—	(98,669)	(98,669)
Balance at March 31, 2024	82,280,827	$823	$2,202,146	$(921)	$(1,288,558)	$913,490
Vesting of restricted common stock	72,040	1	(1)	—	—	—
Stock-based compensation	—	—	31,604	—	—	31,604
Exercise of common stock options	33,343	—	240	—	—	240
Other comprehensive income (loss)	—	—	—	(189)	—	(189)
Net loss	—	—	—	—	(91,051)	(91,051)
Balance at June 30, 2024	82,386,210	$824	$2,233,989	$(1,110)	$(1,379,609)	$854,094
Purchase of common stock under ESPP	58,726	1	1,223	—	—	1,224
Vesting of restricted common stock	82,739	1	(1)	—	—	—
Stock-based compensation	—	—	29,559	—	—	29,559
Exercise of common stock options	31,208	—	239	—	—	239
Other comprehensive income (loss)	—	—	—	2,869	—	2,869
Net loss	—	—	—	—	(96,668)	(96,668)
Balance at September 30, 2024	82,558,883	$826	$2,265,009	$1,759	$(1,476,277)	$791,317

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.